Drug firm Lupin Friday said it has launched in the US its generic Clobazam tablets used for adjunctive treatment of seizures associated with epilepsy that begins early in life.
The company has launched Clobazam tablets in the strengths of 10 mg and 20 mg, after having received an approval from the United States Food and Drug Administration, Lupin said in a statement.
The product is a generic version of Lundbeck Pharms LLC's Onfi tablets in the same strengths, it added.
As per IQVIA MAT March 2019 data, Clobazam tablets, in the two strengths, had an annual sales of around USD 479 million in the US, Lupin said.
The tablets are indicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients two years of age or older, it added.
Shares of Lupin were trading at Rs 849.70 per scrip on BSE, down 1.67 per cent from the previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app